Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vitamin K--what, why, and when.

E Hey1

  • 1shey@easynet.co.uk

Archives of Disease in Childhood. Fetal and Neonatal Edition
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Vitamin K prophylaxis for newborns, primarily for hemorrhagic disease of the newborn, has been manufacturer-driven. A 1mg IM dose unexpectedly prevents late-onset bleeding, with new oral options emerging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PREM score: a graphical tool for predicting survival in very preterm births.

Archives of disease in childhood. Fetal and neonatal edition·2009
Same author

How effectively can clinical examination pick up congenital heart disease at birth?

Archives of disease in childhood. Fetal and neonatal edition·2006
Same author

Can all neonatal resuscitation be managed by nurse practitioners?

Archives of disease in childhood. Fetal and neonatal edition·2005
Same author

Learning from the sad, sorry saga at Stoke.

Archives of disease in childhood·2002
Same author

Abuse of people trying to protect children from abuse.

Lancet (London, England)·2001
Same author

Open letter to the chief medical officer.

BMJ (Clinical research ed.)·2001
Same journal

Postnatally acquired cytomegalovirus infection in preterm infants: an update on diagnosis, management and outcomes.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same journal

High versus low PEEP in the delivery room: a preimplementation and postimplementation cohort study.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same journal

Trends in the incidence of low-grade intraventricular haemorrhage among preterm babies: a national cohort study.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same journal

Apnoeic oxygenation with nasal high flow during neonatal intubation: a prospective audit.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same journal

Visual acuity assessments at 5 years in a national cohort (EPIPAGE-2).

Archives of disease in childhood. Fetal and neonatal edition·2026
Same journal

Clinicians' attitudes to the West Midlands damage control surgery pathway for severe necrotising enterocolitis.

Archives of disease in childhood. Fetal and neonatal edition·2026
See all related articles

Area of Science:

  • Neonatal Medicine
  • Pediatric Pharmacology

Background:

  • Current vitamin K prophylaxis policies for newborns are largely based on manufacturer offerings rather than infant needs or ease of administration.
  • The standard 1 mg intramuscular (IM) dose, intended for early vitamin deficiency bleeding (hemorrhagic disease of the newborn), was found to incidentally protect against late-onset deficiency bleeding.

Discussion:

  • The historical development of vitamin K policies has prioritized commercial availability over optimal infant care strategies.
  • Late-onset vitamin K deficiency bleeding was not recognized when current prophylactic policies were established.

Key Insights:

  • Vitamin K prophylaxis guidelines have historically been influenced by commercial product availability, not solely by infant physiological requirements.
  • The 1 mg IM vitamin K dose offers protection against both early and late forms of vitamin deficiency bleeding in newborns.

Related Experiment Videos

Outlook:

  • Emerging oral vitamin K prophylaxis strategies require further development to ensure ease of administration in diverse global settings.
  • Future vitamin K prophylaxis policies should prioritize evidence-based infant needs and practical delivery methods over manufacturer-driven options.